Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 16, 2023; 11(5): 1058-1067
Published online Feb 16, 2023. doi: 10.12998/wjcc.v11.i5.1058
Published online Feb 16, 2023. doi: 10.12998/wjcc.v11.i5.1058
Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer
Jian-Jing Liang, Department of Medicine, Hebei University, Baoding 071000, Hebei Province, China
Wen-Jing Feng, Run-Tao Xu, Yu-Long Liang, Department of General Surgery, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, Hebei Province, China
Ru Li, Department of Cardiology, First Hospital of Xinji City, Xinji 052300, Hebei Province, China
Author contributions: Liang JJ and Liang YL were responsible for the concept and writing of the manuscript; Liang JJ and Feng WJ analyzed the data; Feng WJ, Li R and Xu RT were responsible for collecting data and revising the paper; all authors have read and agreed to the published version of the manuscript.
Institutional review board statement: The study was reviewed and approved by Ethics Committee of the Third Hospital of Hebei Medical University.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu-Long Liang, MM, Associate Chief Physician, Associate Professor, Department of General Surgery, the Third Hospital of Hebei Medical University, No. 139 Ziqiang Road, Qiaoxi District, Shijiazhuang 050051, Hebei Province, China.
Received: December 5, 2022
Peer-review started: December 5, 2022
First decision: December 26, 2022
Revised: January 4, 2023
Accepted: January 16, 2023
Article in press: January 16, 2023
Published online: February 16, 2023
Processing time: 70 Days and 21.1 Hours
Peer-review started: December 5, 2022
First decision: December 26, 2022
Revised: January 4, 2023
Accepted: January 16, 2023
Article in press: January 16, 2023
Published online: February 16, 2023
Processing time: 70 Days and 21.1 Hours
Core Tip
Core Tip: Thyroid carcinoma (TC) is the most common cancer in the endocrine system. It has been established that thyroid-stimulating hormone (TSH) stimulates the growth and development of thyroid malignancy, and a higher serum TSH level is associated with the incidence of thyroid cancer and an advanced tumor stage. This study aims to explore the clinical value of TSH in regulating the progress of TC, which can provide a new direction for thyroid therapy.